drugset / Trial / NCT03520959
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
Timeline
- Start
- 2018-09-18
- Primary completion
- 2018-11-20
- Completion
- 2018-11-20
Outcome
Outcome not reported
Stopped: “Study was terminated due to sponsor's decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G305 | Protein / enzyme biologic | — | Intramuscular |
| Subject | LV305 | Unknown | — | Subcutaneous |